MTMT-ben szereplő publikációk tallózása szerző szerint "Pap E"

1-3 / 3

Nagy dózisú methotrexatkezelések farmakokinetikai vizsgálata gyermekkori hematológiai malignitásokban

Csordas, Katalin; Eipel, Olivér; Hegyi, Márta; Csóka, Monika; Pap E; Kovács, Gábor (2011)

Monitoring the pharmacokinetic parameters of different anticancer drugs is necessary because they might have several side effects. Aim: Pharmacokinetic and toxicity evaluation of high-dose methotrexate treatments in children ...
SHMT1 1420 and MTHFR 677 variants are associated with rectal but not colon cancer.

Komlósi, Lajos Viktor; Hitre, Erika; Pap E; Adleff V; Réti, Andrea; Székely, Éva; Biro A; Rudnai P; Schoket B; Müller, Judit; Tóth, Béla; Szabolcs, Ottó; Kásler, Miklós; Kralovánszky, Judit; Budai, Barna (2010)

BACKGROUND: Association between rectal or colon cancer risk and serine hydroxymethyltransferase 1 (SHMT1) C1420T or methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms was assessed. The serum total homocysteine ...
Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism.

Müller, Judit; Kralovánszky, Judit; Adleff V; Pap E; Németh, Krisztina; Komlósi, Lajos Viktor; Kovács, Gábor (2008)

BACKGROUND: High-dose methotrexate (HD-MTX) is one of the most important agents in the therapy of osteosarcoma (OSC). Acute and delayed toxicities still constitute clinical problems. Methylenetetrahydrofolate reductase ...

1-3 / 3

Keresés